CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

BACKGROUND: The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational. In this study, we aimed to determine the clini...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Commun (Lond)
Главные авторы: Shi, Yuankai, Li, Jin, Xu, Jianming, Sun, Yan, Wang, Liwei, Cheng, Ying, Liu, Wei, Sun, Guoping, Chen, Yigui, Bai, Li, Zhang, Yiping, He, Xiaohui, Luo, Yi, Wang, Zhehai, Liu, Yunpeng, Yao, Qiang, Li, Yuhong, Qin, Shukui, Hu, Xiaohua, Bi, Feng, Zheng, Rongsheng, Ouyang, Xuenong
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534840/
https://ncbi.nlm.nih.gov/pubmed/31126331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0374-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы